Drug Cos. See Path To Legal Off-Label Marketing

Law360, New York (May 10, 2013, 7:07 PM EDT) -- The drug industry is using a Second Circuit ruling that blocked the U.S. Food and Drug Administration from prosecuting a salesman for promoting a drug for off-label uses to push the agency to adopt regulations that would allow for truthful off-label marketing, hoping the change would significantly boost drug sales.

The Pharmaceutical Research and Manufacturers of America, the major trade group for the name-brand drug industry, would like to see the FDA change its regulations to allow off-label promotion, as long as the information shared is...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.